Opendata, web and dolomites

ExtremoChem

Chemically synthesised novel compounds for the stabilisation of biologics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExtremoChem project word cloud

Explore the words cloud of the ExtremoChem project. It provides you a very rough idea of what is the project "ExtremoChem" about.

market    20    direct    12    least    savings    critical    agitation    elaborate    tests    biological    clinical    salinity    preserve    volume    purification    medical    white    prepare    proteins    extremochem    blood    mabs    consisting    degradation    industrial    stability    feasible    protects    temperatures    carbons    organic    interferins    lower    storage    obtain    medicines    stressful    synthesises    molecules    safety    wasted    revenues    thermally    arthritis    sign    compounds    issue    size    suitable    validation    assuring    biopharmaceutical    stabilization    small    otherwise    restored    native       sensitive    business    chain    vaccines    biopharmaceuticals    reachable    strict    cells    degrade    lost    extraction    stages    ph    biotechnology    biologic    quality    humira    cold    once    source    insulins    neupogen    synthetic    material    share    subject    rheumatoid    plan    full    commercial    effectiveness    sound    trial    line    stabilise    potency    preventing    biologics    drugs    aggregation   

Project "ExtremoChem" data sheet

The following table provides information about the project.

Coordinator
EXTREMOCHEM LDA 

Organization address
address: Estrada Municipal 528, 1
city: IGREJINHA
postcode: 7040-220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://extremochem.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXTREMOCHEM LDA PT (IGREJINHA) coordinator 50˙000.00

Map

 Project objective

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted.

ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues.

The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXTREMOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXTREMOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More